Aurobindo Pharma officials to attend UBS virtual investor meet

0 min read Updated on 06 Jun 2026, 12:21 PM

Reviewed by

Anirudha BScanX News Team

AI Summary

Aurobindo Pharma Limited announced that its officials will participate in the UBS - Virtual Generics and Biosimilar Day, a virtual investor meeting scheduled for June 10, 2026, from 19:00 to 20:00 IST. The company confirmed that no unpublished price sensitive information will be discussed during the event. The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited on June 5, 2026, by B. Adi Reddy, Company Secretary.

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma Limited officials will participate in a virtual investor meeting hosted by UBS on June 10, 2026, to discuss industry trends. The meeting, titled UBS - Virtual Generics and Biosimilar Day, is scheduled from 19:00 to 20:00 IST. The company clarified that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction.

The participation was communicated to the National Stock Exchange of India Limited and BSE Limited on June 5, 2026. The schedule of the meeting remains subject to change due to exigencies on the part of the investor or the company.

Meeting Details

Date	Time	Investor/Meeting name	Type of meeting	Location
June 10, 2026	19:00 to 20:00 (IST)	UBS - Virtual Generics and Biosimilar Day	Group meeting	Virtual

The disclosure was made by B. Adi Reddy, Company Secretary of Aurobindo Pharma . The filing was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations.

Historical Stock Returns for Aurobindo Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.61%	+9.34%	+6.27%	+28.38%	+40.84%	+65.76%

What key industry trends in the generics and biosimilar sectors are expected to dominate discussions during the meeting?

How might Aurobindo Pharma's strategic focus shift in response to evolving market dynamics in the generics space?

What potential regulatory changes could impact the biosimilar market, and how is Aurobindo preparing for them?

Read Next Article

Aurobindo Pharma Receives Final US FDA Approval for Tofacitinib Tablets in 5 mg and 10 mg Strengths

0 min read Updated on 05 Jun 2026, 05:36 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

Aurobindo Pharma has received final US FDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths, marking a key regulatory milestone. The approval underscores the company's commitment to FDA quality standards and further strengthens its generics pipeline for the US market.

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma has secured final approval from the United States Food and Drug Administration (US FDA) for Tofacitinib Tablets in two strengths — 5 mg and 10 mg. This regulatory milestone adds another product to the company's growing portfolio of US FDA-approved generic formulations.

Regulatory Approval Details

The final US FDA approval covers Tofacitinib Tablets across both available strengths, as outlined below:

Parameter:	Details
Product:	Tofacitinib Tablets
Strengths Approved:	5 mg and 10 mg
Regulatory Authority:	US Food and Drug Administration (US FDA)
Approval Type:	Final Approval

Significance of the Approval

The receipt of final US FDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths marks a significant regulatory achievement for Aurobindo Pharma. The approval reflects the company's ongoing commitment to meeting the stringent quality and compliance standards set by the US FDA for generic pharmaceutical products. This development further strengthens Aurobindo Pharma's generics pipeline targeting the US market.

Historical Stock Returns for Aurobindo Pharma